Antigen-specific TIL therapy for melanoma: a flexible platform for personalized cancer immunotherapy by Sander Kelderman et al.
POSTER PRESENTATION Open Access
Antigen-specific TIL therapy for melanoma:
a flexible platform for personalized cancer
immunotherapy
Sander Kelderman1*, Bianca Heemskerk1, Mireille Toebes1, Marit van Buuren1, Nienke van Rooij1, Laura Bies1,
Lorenzo Fanchi1, Lothar Germeroth2, Pia Kvistborg1, Ton Schumacher1
From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013
Adoptive cell therapy (ACT) for melanoma has shown to
be an effective treatment modality with clinical responses
in approximately 50% of stage IV disease patients. How-
ever, durable complete responses are observed in only a
small proportion (10-20%) of patients. Recent data have
demonstrated that the tumor-infiltrating lymphocyte
(TIL) infusion products used for therapy harbor only low
frequencies of T cells reactive against presently known
shared melanoma-associated epitopes. Furthermore,
ongoing studies indicate that T cell reactivity against
patient-specific mutated antigens may be common in
human melanoma. Collectively, these two observations
suggest that the development of a clinically applicable
approach that allows the selection of defined tumor-reac-
tive T cell populations in a patient-specific manner
would be of value. Here we develop such a platform tech-
nology and demonstrate its value in a preclinical model.
First, reversible (strep-tagged) HLA-A*0201 molecules
for clinical use were produced with a UV-sensitive pep-
tide ligand, and the resulting MHC class I monomers
could be loaded with peptides of interest in straightfor-
ward peptide exchange reactions. To subsequently evalu-
ate the potential of these MHC exchange streptamers for
antigen-specific T cell enrichment, we performed indivi-
dual or combined enrichments of melanoma-reactive
T cell populations from TIL populations. Enrichment of
both high (1≥%) and low frequency (<1%) tumor-specific
T cell populations, either alone or combined, was shown
to be feasible with a mean enrichment factor of 27 and 56.
To evaluate the potential of this technology for the genera-
tion of T cell products that recognize patient-specific
neo-antigens, we performed combined enrichments of two
HLA-A*0201 restricted T cell responses, directed against
neo-antigens in the CDK4 (2.2% of CD8+ cells) and
GCN1L1 (0.58% of CD8+ cells) gene products that we
identified by exome sequencing. Combined enrichment of
these two patient-specific T cell populations resulted in a
neo-antigen specific cell product with a purity of 92.4%.
Functional analysis of the neo-antigen selected T cell pro-
duct against autologous tumor in NSG mice showed
superior tumor control and survival compared to non-
selected ‘standard’ TIL. Together, these data demonstrate
that selection of (panels of) antigen-specific T cells using
the combination of UV-induced ligand exchange and
reversible streptamer technology is feasible. In combina-
tion with exome-driven analysis of tumor-specific T cell
reactivity in human cancer, this strategy forms a highly
flexible platform for the development of antigen-specific
cell products for personalized cancer immunotherapy.
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